Chronic Myeloid Leukemia Extended

Karyotyping involves the examination of chromosomes in a cell. In CML, Karyotyping is used to detect the presence of the Philadelphia chromosome, which is a diagnostic hallmark of the disease.

BCR/ABL by FISH (Fluorescence In Situ Hybridization) is a technique used to detect the BCR-ABL gene fusion at the DNA level. This gene fusion is characteristic of CML and confirms the diagnosis.

The BCR/ABL- IS by PCR Quantitative test is highly sensitive and measures the amount of BCR-ABL mRNA in the blood. It is used to monitor the patient’s response to therapy, and changes in levels can indicate whether the disease is responding to treatment or progressing.

The Philadelphia chromosome is an abnormal chromosome produced when parts of chromosomes 9 and 22 swap places. This leads to the creation of the BCR-ABL fusion gene which produces an abnormal protein that promotes the growth of leukemia cells.

Early diagnosis of CML is important because it is more treatable in the early stages. Early treatment can help to control the progression of the disease and improve the chances of a positive outcome.

The frequency of the CML Extended test depends on the stage of the disease and the patient’s response to treatment. It is usually done at diagnosis and regularly during treatment to monitor the response.

The common treatment for CML is tyrosine kinase inhibitors (TKIs). These medications block the action of the BCR-ABL protein. Other treatments may include chemotherapy, stem cell transplant, and immunotherapy.

Patients with CML should maintain a balanced diet, stay physically active, avoid smoking and excessive alcohol consumption, and adhere to the treatment and monitoring plan recommended by the doctor.

CML treatments, particularly tyrosine kinase inhibitors, can have side effects such as fatigue, nausea, muscle pain, and changes in blood counts. The healthcare team will monitor and manage side effects during treatment.

If diagnosed with Chronic Myeloid Leukemia, it is imperative to consult a hematologist or oncologist specializing in the treatment of blood cancers.

Yes, there are support groups and organizations that offer help and support to individuals with CML and their families.

CML is not typically hereditary. It is caused by a genetic change that occurs during a person’s lifetime.

CML Extended testing is crucial for the diagnosis, prognosis, and monitoring of Chronic Myeloid Leukemia. It provides in-depth genetic information that is vital for understanding the nature of the disease and planning treatment. Regular monitoring through CML Extended testing is an integral part of managing CML and adjusting treatment plans. Consultation with a hematologist or oncologist is critical for comprehensive care and management.